Journal Article
. 2022 Mar; 13:828319.
doi: 10.3389/fimmu.2022.828319.

An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models

Xin Chen 1 Liu Xue 2 Xiao Ding 3 Jing Zhang 2 Lei Jiang 1 Sha Liu 1 Hongjia Hou 1 Bin Jiang 3 Liang Cheng 2 Qing Zhu 2 Lijie Zhang 3 Xiaosui Zhou 1 Jie Ma 2 Qi Liu 2 Yucheng Li 2 Zhiying Ren 2 Beibei Jiang 1 Xiaomin Song 1 Jing Song 2 Wei Jin 3 Min Wei 2 Zhirong Shen 3 Xuesong Liu 1 Lai Wang 1 Kang Li 2 Tong Zhang 1 
  • PMID: 35273608
  •     36 References


TIGIT (T-cell immunoglobulin and ITIM domain) has emerged as a promising target in cancer immunotherapy. It is an immune "checkpoint" inhibitor primarily expressed on activated T cells, NK cells and Tregs. Engagement of TIGIT to its ligands PVR and PVR-L2 leads to inhibitory signaling in T cells, promoting functional exhaustion of tumor-infiltrating T lymphocytes. Here, we described the pre-clinical characterization of Ociperlimab (BGB-A1217), a novel humanized IgG1 anti-TIGIT antibody (mAb), and systemically evaluated the contribution of Fc functions in the TIGIT mAb-mediated anti-tumor activities. BGB-A1217 binds to the extracellular domain of human TIGIT with high affinity (KD = 0.135 nM) and specificity, and efficiently blocks the interaction between TIGIT and its ligands PVR or PVR-L2. Cell-based assays show that BGB-A1217 significantly enhances T-cell functions. In addition, BGB-A1217 induces antibody dependent cellular cytotoxicity (ADCC) against Treg cells, activates NK cells and monocytes, and removes TIGIT from T cell surfaces in an Fc-dependent manner, In vivo, BGB-A1217, either alone or in combination with an anti-PD-1 mAb elicits strong immune responses and potent anti-tumor efficacy in pre-clinical models. Moreover, the Fc effector function is critical for the anti-tumor activity of BGB-A1217 in a syngeneic human TIGIT-knock-in mouse model. The observed anti-tumor efficacy is associated with a pharmacodynamic change of TIGIT down-regulation and Treg reduction. These data support the selection of BGB-A1217 with an effector function competent Fc region for clinical development for the treatment of human cancers.

Keywords: BGB-A1217; Fc effector function; TIGIT; antibody; cancer immunotherapy; immune checkpoint; ociperlimab.

Expression of immune checkpoint receptors Indoleamine 2,3-dioxygenase and T cell Ig and ITIM domain in metastatic versus nonmetastatic choroidal melanoma.
Gustav Stålhammar, Stefan Seregard, Hans E Grossniklaus.
Cancer Med, 2019 Apr 18; 8(6). PMID: 30993893    Free PMC article.
Expression of lymphocyte-activating gene 3 and T-cell immunoreceptor with immunoglobulin and ITIM domains in cutaneous melanoma and their correlation with programmed cell death 1 expression in tumor-infiltrating lymphocytes.
Woo Jin Lee, Ye Jin Lee, +5 authors, Sung Eun Chang.
J Am Acad Dermatol, 2019 Mar 19; 81(1). PMID: 30880064
Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity.
Tom van Meerten, Rozemarijn S van Rijn, +2 authors, Saskia B Ebeling.
Clin Cancer Res, 2006 Jul 05; 12(13). PMID: 16818702
Divergent Phenotypes of Human Regulatory T Cells Expressing the Receptors TIGIT and CD226.
Christopher A Fuhrman, Wen-I Yeh, +15 authors, Todd M Brusko.
J Immunol, 2015 May 23; 195(1). PMID: 25994968    Free PMC article.
TIGIT predominantly regulates the immune response via regulatory T cells.
Sema Kurtulus, Kaori Sakuishi, +6 authors, Ana C Anderson.
J Clin Invest, 2015 Sep 29; 125(11). PMID: 26413872    Free PMC article.
Highly Cited.
T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients.
Yaxian Kong, Liuluan Zhu, +7 authors, Hong Zheng.
Clin Cancer Res, 2016 Jan 15; 22(12). PMID: 26763253
Highly Cited.
Restoration of T-cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist Antibodies.
Julie Preillon, Julia Cuende, +24 authors, Catherine Hoofd.
Mol Cancer Ther, 2020 Dec 06; 20(1). PMID: 33277440
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma.
Inger S Nijhof, Tineke Casneuf, +14 authors, Niels W C J van de Donk.
Blood, 2016 Jun 17; 128(7). PMID: 27307294
Highly Cited.
The TIGIT/CD226 axis regulates human T cell function.
Ester Lozano, Margarita Dominguez-Villar, Vijay Kuchroo, David A Hafler.
J Immunol, 2012 Mar 20; 188(8). PMID: 22427644    Free PMC article.
Highly Cited.
Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.
Mark J Selby, John J Engelhardt, +4 authors, Alan J Korman.
Cancer Immunol Res, 2014 Apr 30; 1(1). PMID: 24777248
Highly Cited.
Molecular mechanisms of T cell co-stimulation and co-inhibition.
Lieping Chen, Dallas B Flies.
Nat Rev Immunol, 2013 Mar 09; 13(4). PMID: 23470321    Free PMC article.
Highly Cited. Review.
Effective Anti-tumor Response by TIGIT Blockade Associated With FcγR Engagement and Myeloid Cell Activation.
Jin-Hwan Han, Mingmei Cai, +9 authors, Sybil M Genther Williams.
Front Immunol, 2020 Oct 30; 11. PMID: 33117369    Free PMC article.
The Role and Function of Fcγ Receptors on Myeloid Cells.
Stylianos Bournazos, Taia T Wang, Jeffrey V Ravetch.
Microbiol Spectr, 2017 Jan 15; 4(6). PMID: 28087938    Free PMC article.
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies.
Frederick Arce Vargas, Andrew J S Furness, +32 authors, Sergio A Quezada.
Cancer Cell, 2018 Mar 27; 33(4). PMID: 29576375    Free PMC article.
Highly Cited.
FcγR-Binding Is an Important Functional Attribute for Immune Checkpoint Antibodies in Cancer Immunotherapy.
Xin Chen, Xiaomin Song, Kang Li, Tong Zhang.
Front Immunol, 2019 Mar 14; 10. PMID: 30863404    Free PMC article.
Highly Cited. Review.
TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.
Joe-Marc Chauvin, Ornella Pagliano, +8 authors, Hassane M Zarour.
J Clin Invest, 2015 Apr 14; 125(5). PMID: 25866972    Free PMC article.
Highly Cited.
Characterization of ASP8374, a fully-human, antagonistic anti-TIGIT monoclonal antibody.
Kenna Shirasuna, Gerald Koelsch, +12 authors, Taku Yoshida.
Cancer Treat Res Commun, 2021 Jul 18; 28. PMID: 34273876
Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies.
Yannick Bulliard, Rose Jolicoeur, +6 authors, Jennifer L Brogdon.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897982    Free PMC article.
Highly Cited.
The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells.
Xin Yu, Kristin Harden, +9 authors, Jane L Grogan.
Nat Immunol, 2008 Nov 18; 10(1). PMID: 19011627
Highly Cited.
Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses.
Nicole Joller, Ester Lozano, +13 authors, Vijay K Kuchroo.
Immunity, 2014 Apr 22; 40(4). PMID: 24745333    Free PMC article.
Highly Cited.
CD226 opposes TIGIT to disrupt Tregs in melanoma.
Julien Fourcade, Zhaojun Sun, +11 authors, Hassane M Zarour.
JCI Insight, 2018 Jul 27; 3(14). PMID: 30046006    Free PMC article.
Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells.
S Liu, H Zhang, +5 authors, Z Fan.
Cell Death Differ, 2012 Nov 17; 20(3). PMID: 23154388    Free PMC article.
The function of Fcγ receptors in dendritic cells and macrophages.
Martin Guilliams, Pierre Bruhns, +2 authors, Bart N Lambrecht.
Nat Rev Immunol, 2014 Jan 22; 14(2). PMID: 24445665
Highly Cited. Review.
Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes.
Paul V Beum, David A Mack, +2 authors, Ronald P Taylor.
J Immunol, 2008 Nov 20; 181(11). PMID: 19018005
The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity.
Noa Stanietsky, Hrvoje Simic, +11 authors, Ofer Mandelboim.
Proc Natl Acad Sci U S A, 2009 Oct 10; 106(42). PMID: 19815499    Free PMC article.
Highly Cited.
A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC.
Kent S Boles, William Vermi, +5 authors, Marco Colonna.
Eur J Immunol, 2009 Feb 07; 39(3). PMID: 19197944    Free PMC article.
Two amino acid mutations in an anti-human CD3 single chain Fv antibody fragment that affect the yield on bacterial secretion but not the affinity.
S M Kipriyanov, G Moldenhauer, +2 authors, M Little.
Protein Eng, 1997 Apr 01; 10(4). PMID: 9194170
OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy.
Yannick Bulliard, Rose Jolicoeur, +3 authors, Jennifer L Brogdon.
Immunol Cell Biol, 2014 Apr 16; 92(6). PMID: 24732076
Highly Cited.
CD155T/TIGIT Signaling Regulates CD8+ T-cell Metabolism and Promotes Tumor Progression in Human Gastric Cancer.
Weiling He, Hui Zhang, +12 authors, Zunfu Ke.
Cancer Res, 2017 Sep 09; 77(22). PMID: 28883004
T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling.
Sarah E Josefsson, Kanutte Huse, +10 authors, June H Myklebust.
Clin Cancer Res, 2017 Dec 09; 24(4). PMID: 29217528    Free PMC article.
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R Simpson, Fubin Li, +11 authors, Sergio A Quezada.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897981    Free PMC article.
Highly Cited.
Fcγ-receptor-mediated trogocytosis impacts mAb-based therapies: historical precedence and recent developments.
Ronald P Taylor, Margaret A Lindorfer.
Blood, 2014 Dec 17; 125(5). PMID: 25498911
Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab.
Jakub Krejcik, Kris A Frerichs, +15 authors, Niels W C J van de Donk.
Clin Cancer Res, 2017 Oct 14; 23(24). PMID: 29025767    Free PMC article.
Highly Cited.
The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function.
Robert J Johnston, Laetitia Comps-Agrar, +9 authors, Jane L Grogan.
Cancer Cell, 2014 Dec 04; 26(6). PMID: 25465800
Highly Cited.
COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade.
Kyle Hansen, Sandeep Kumar, +17 authors, Maya F Kotturi.
Cancer Immunol Immunother, 2021 Apr 28; 70(12). PMID: 33903974
Ex vivo neutralization of HIV-1 quasi-species by a broadly reactive humanized monoclonal antibody KD-247.
Shuzo Matsushita, Soichiro Takahama, +6 authors, Kazuhisa Yoshimura.
Hum Antibodies, 2006 May 25; 14(3-4). PMID: 16720978